Find Clinical Trials

March 1, 2024 in Hematology

M20-621/EPCORE DLBCL-2

A Phase 3, Randomized, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP Compared to R-CHOP in Subjects with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)…
Read More
February 28, 2024 in Hematology

S2209

A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or in a Subset of “Intermediate Fit” Comparing Upfront Three-drug Induction Regimens Followed by Double- or…
Read More
January 22, 2024 in Hematology

CVAY736I12301/VAYHIT1

A phase III, randomized, double-blind study of ianalumab (VAY736) versus placebo in addition to first-line corticosteroids in primary immune thrombocytopenia (VAYHIT1)  
Read More
June 28, 2023 in Hematology

ASC4START/CABL001J12302

A phase IIIb, multi-center, open-label, randomized study of tolerability and efficacy of oral asciminib versus nilotinib in patients with newly diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase
Read More
November 9, 2022 in Hematology

EA9152

A Phase Ib/II Study of Venetoclax (ABT-199) in Combination with Liposomal Vincristine in Patients with Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia
Read More
September 14, 2022 in Hematology

S1803

S1803: Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct…
Read More
July 11, 2022 in Hematology

S1925

S1925: Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus DeLayed Therapy with VEnetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia (CLL)/Small…
Read More
July 11, 2022 in Hematology

S1608

Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma
Read More
June 30, 2022 in Hematology

EAA181

EAA181: Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation (NCT04566328)
Read More
June 30, 2022 in Hematology

EAA173

EAA173: Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)
Read More
June 30, 2022 in Hematology

EA6174

EA6174-A Phase III Randomized Trial Comparing Adjuvant MK-3775 (Pembrolizumab) to Standard of Care Observation in Completely Resected Merkel Cell Carcinoma
Read More
June 30, 2022 in Hematology

CONNECT Myeloid

The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry
Read More
June 30, 2022 in Hematology

ANHL1931

ANHL1931: A Randomized Phase 3 trial of Nivolumab in Combination with Chemo-immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell Lymphoma
Read More
June 30, 2022 in Hematology

A041701

A041701: A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults with Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
Read More
June 30, 2022 in Hematology

A041501

A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) with Newly…
Read More